GYREGyre Therapeutics, Inc.
Price
-26%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
Quality strong, a flag to check, growth steady, the market undecided.
Charts
As reported to the SEC, without any scoring.
Gyre Therapeutics, Inc. (GYRE) reported revenue of $29M in Q2 2026 (quarter ended Jun 30, 2026), down 2.1% from the same quarter a year earlier. That came with a gross margin of 92% and net loss of $14M. For the full year FY2025, revenue was $117M (+10% year on year) and net income $9.9M. The next results filing is expected around Nov 6, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Oct 22, 2026On October 16, 2026, Gyre Therapeutics, Inc. (“Gyre”) entered into an employment agreement with Ying Luo, Ph.D. (the “Luo Employment Agreement”), to continue to serve as Gyre’s Chief Executive Officer.Director or officer change · Form 8-K
- Sep 1, 20261 September 2026 A Global Innovator Expanding And Reinventing Protein Degrader.Regulation FD disclosure · press release
- Aug 26, 20261 August 2026 Building A New Protein Degrader Company For Unmet Medical Needs.Regulation FD disclosure · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.